Journal for ImmunoTherapy of Cancer (Nov 2023)
877 Intermittent dosing of the ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib promotes antitumor immunity by remodelling the tumor immune microenvironment in pre-clinical models
- Matthew King,
- Dmitry Gabrilovich,
- Simon Barry,
- Mark Cobbold,
- Viia Valge-Archer,
- Adina Hughes,
- Elizabeth Hardaker,
- Alison Peter,
- Anisha Solanki,
- Lukasz Magiera,
- Gozde Kar,
- Stephen Fawell,
- Ankur Karmokar,
- Marta Milo,
- Chrysiis Michaloglou,
- Ricardo Miragaia,
- Sara Talbot,
- Carolyn Lam,
- Daniel Sutton,
- Scott Hoffmann,
- Larissa Carnevalli,
- Zena Wilson,
- Alan Lau
Affiliations
- Matthew King
- 1AstraZeneca, Cambridge, UK
- Dmitry Gabrilovich
- 3AstraZeneca, Gaithersburg, MD, USA
- Simon Barry
- 1AstraZeneca, Cambridge, UK
- Mark Cobbold
- 3AstraZeneca, Gaithersburg, MD, USA
- Viia Valge-Archer
- 1AstraZeneca, Cambridge, UK
- Adina Hughes
- 1AstraZeneca, Cambridge, UK
- Elizabeth Hardaker
- 1AstraZeneca, Cambridge, UK
- Alison Peter
- 1AstraZeneca, Cambridge, UK
- Anisha Solanki
- 1AstraZeneca, Cambridge, UK
- Lukasz Magiera
- 1AstraZeneca, Cambridge, UK
- Gozde Kar
- 1AstraZeneca, Cambridge, UK
- Stephen Fawell
- 2AstraZeneca, Waltham, MA, USA
- Ankur Karmokar
- 1AstraZeneca, Cambridge, UK
- Marta Milo
- 1AstraZeneca, Cambridge, UK
- Chrysiis Michaloglou
- 1AstraZeneca, Cambridge, UK
- Ricardo Miragaia
- 1AstraZeneca, Cambridge, UK
- Sara Talbot
- 1AstraZeneca, Cambridge, UK
- Carolyn Lam
- 1AstraZeneca, Cambridge, UK
- Daniel Sutton
- 1AstraZeneca, Cambridge, UK
- Scott Hoffmann
- 1AstraZeneca, Cambridge, UK
- Larissa Carnevalli
- 1AstraZeneca, Cambridge, UK
- Zena Wilson
- 1AstraZeneca, Cambridge, UK
- Alan Lau
- 1AstraZeneca, Cambridge, UK
- DOI
- https://doi.org/10.1136/jitc-2023-SITC2023.0877
- Journal volume & issue
-
Vol. 11,
no. Suppl 1
Abstract
No abstracts available.
